Veradermics (MANE) Cash from Financing Activities (2025 - 2026)
Veradermics (MANE) posted Cash from Financing Activities of $269.1 million for Q1 2026, up 3094.98% on a QoQ basis from $8.4 million in Q1 2025, and up 3094.98% year-over-year from $8.4 million in Q1 2025.
Veradermics (MANE) Cash from Financing Activities (2025 - 2026) Analysis & Trends
Veradermics' Cash from Financing Activities history runs 2 years deep, the most recent figure standing at $269.1 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Veradermics | 2.63 Bn | 2.63 Bn | - | 269.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 269.11 Mn |
| Mar 31, 2026 | 269.11 Mn |
| Mar 31, 2025 | 8.42 Mn |
| Mar 31, 2025 | 8.42 Mn |